A novel KCNA1 mutation in a patient with paroxysmal ataxia, myokymia, painful contractures and metabolic dysfunctions.

Paola Imbrici, Concetta Altamura, Francesca Gualandi, Giuseppe Felice Mangiatordi, Marcella Neri, Giovanni De Maria, Alessandra Ferlini, Alessandro Padovani, Maria Cristina D'Adamo, Orazio Nicolotti, Mauro Pessia, Diana Conte, Massimiliano Filosto, Jean-Francois Desaphy

Journal: Molecular and cellular neurosciences 2018;83():6-12

PMID: 28666963

Abstract

Episodic ataxia type 1 (EA1) is a human dominant neurological syndrome characterized by continuous myokymia, episodic attacks of ataxic gait and spastic contractions of skeletal muscles that can be triggered by emotional stress and fatigue. This rare disease is caused by missense mutations in the KCNA1 gene coding for the neuronal voltage gated potassium channel Kv1.1, which contributes to nerve cell excitability in the cerebellum, hippocampus, cortex and peripheral nervous system. We identified a novel KCNA1 mutation, E283K, in an Italian proband presenting with paroxysmal ataxia and myokymia aggravated by painful contractures and metabolic dysfunctions. The E283K mutation is located in the S3-S4 extracellular linker belonging to the voltage sensor domain of Kv channels. In order to test whether the E283K mutation affects Kv1.1 biophysical properties we transfected HEK293 cells with WT or mutant cDNAs alone or in a 1:1 combination, and recorded relative potassium currents in the whole-cell configuration of patch-clamp. Mutant E283K channels display voltage-dependent activation shifted by 10mV toward positive potentials and kinetics of activation slowed by ~2 fold compared to WT channels. Potassium currents resulting from heteromeric WT/E283K channels show voltage-dependent gating and kinetics of activation intermediate between WT and mutant homomeric channels. Based on homology modeling studies of the mutant E283K, we propose a molecular explanation for the reduced voltage sensitivity and slow channel opening. Overall, our results suggest that the replacement of a negatively charged residue with a positively charged lysine at position 283 in Kv1.1 causes a drop of potassium current that likely accounts for EA-1 symptoms in the heterozygous carrier.

Copyright © 2017 Elsevier Inc. All rights reserved.

Address: Department of Pharmacy - Drug Sciences, University of Bari Aldo Moro, Bari, Italy. Electronic address: [email protected].; Department of Pharmacy - Drug Sciences, University of Bari Aldo Moro, Bari, Italy.; Logistic Unit of Medical Genetics, Department of Medical Sciences, University-Hospital of Ferrara, Italy.; Unit of Neurophysiopathology, ASST "Spedali Civili", Brescia, Italy.; Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology, ASST "Spedali Civili", and University of Brescia, Brescia, Italy.; Faculty of Medicine, Department of Physiology and Biochemistry, University of Malta, MSD-2080 Msida, Malta.; Faculty of Medicine, Department of Physiology and Biochemistry, University of Malta, MSD-2080 Msida, Malta; Department of Experimental Medicine, Section of Physiology & Biochemistry, University of Perugia School of Medicine, Perugia, Italy.; Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy.

Link outs

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.